Navigation Links
Accuray Incorporated CFO Resigns
Date:9/3/2013

SUNNYVALE, Calif., Sept. 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Derek Bertocci has resigned as Senior Vice President and Chief Financial Officer of the company effective September 2, 2013.  Today, Accuray has appointed Gregory Lichtwardt, executive vice president, chief financial officer, effective immediately.  Mr. Bertocci is anticipated to continue in a consulting role with the Company.

Mr. Lichtwardt, age 59, joins Accuray after spending over nine years with Conceptus Inc., where he served as Executive Vice President, Chief Financial Officer. During his time at Conceptus Inc., its sales grew from $8 million to $141 million and adjusted EBITDA reached 20 percent of sales.

Lichtwardt brings to Accuray thirty-three years of financial and operational leadership experience in building technology companies. Prior to joining Conceptus Inc., he served as Executive Vice President, Chief Financial Officer and Corporate Secretary of Innoventry, Inc., a financial services company.  He was previously with Ocular Sciences, Inc. a world-wide developer and marketer of soft contact lenses, as Vice President, Finance and Chief Financial Officer, a company which he took public.  Prior to that, Mr. Lichtwardt held senior management positions with Allergan, Inc. and started his career with American Hospital Supply Corporation.  Mr. Lichtwardt also serves on the board of directors of Biolase, Inc., where he is the chair of the audit committee and participates on the compensation committee.

Commenting on his appointment, Mr. Lichtwardt said, "This is an exciting time to be joining Accuray.  The Company has made significant strides, is led by a talented team and is positioned to achieve significant growth.  I am energized by the challenge and look forward to contributing to the Company's success and drive to profitability."

In making the announcement, Joshua H. Levine, president and chief executive officer of Accuray said, "Greg brings broad medical device industry experience and important leadership skills that will drive the planning and execution of our financial strategies. In addition, Greg will play a significant role at Accuray as we pursue long-term strategic growth opportunities.  We are delighted to have Greg join the Accuray team at this pivotal point in our evolution.  His experiences will prove invaluable as we expand our commercial footprint and shareholder value. I would also like to thank Derek Bertocci for his leadership and guidance over the years at Accuray."

Bertocci had joined Accuray in January 2009 as CFO and during his tenure, Bertocci helped to expand the radiosurgery market with the Company's flagship product, the CyberKnife System.  He was also a key leader of the company through the growth of Accuray as a young public company and through the transformational acquisition of TomoTherapy in 2011.  The acquisition of TomoTherapy added the TomoTherapy System to the Company's product portfolio, which expanded the Company into the radiation therapy market.

"I want to thank the Executive Team, the Board, the investors and Accuray employees for their support and encouragement over the last several years as we together changed the way people think about treating cancer patients," said Bertocci.  "It's been a fulfilling experience, but I feel that after being CFO for almost five years at Accuray and a CFO at various companies for almost ten years that taking a break in my career and taking time to spend with my family is important." 

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to management/leadership capabilities, future profitability, long-term growth, commercial success, shareholder value, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013.  Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking statements.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2013
3. Accuray to Host Investor Meeting at ASTRO 2013
4. Accuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2013
5. Accuray is Honored for Delivering World-Class Customer Service
6. Accuray Incorporated to Present at 2013 Jefferies Global Healthcare Conference
7. Accuray Announces Results for Third Quarter Fiscal 2013
8. Accuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
9. Accuray Provides Clarification on Recently Initiated Voluntary Recalls
10. Dr. Emad Rizk Joins Accuray Board of Directors
11. Accuray Incorporated to Speak at Cowen and Company 33rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Israel and TAMPA, Fla. , ... an emerging medical device company focused on developing ... procedures, applauds the members of the FDA,s Circulatory ... for their acknowledgement of the need for cerebral ... "The statements shared by this FDA ...
(Date:2/27/2017)... 2017 Now in its seventh year, ... are most successful at developing and commercialising innovation. ... The Index can ... molecule to two different companies in early phase, which would ... objective analysis of each company,s performance between 2011 and 2016, the 2017 ...
(Date:2/27/2017)... Period October – December 2016 ... to SEK -16.4 (-6.4) million Result after tax amounted to ... after dilution Cash flow from operating activities amounted to SEK ... Period full ... Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... wholesale distribution in North America, today announced it would be offering some it’s ... which prides itself on crafting quality and unique baby clothing/feeding products, will team ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and ... the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, ...
(Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... (PD) patients after receiving cognitive rehabilitation, according to a study released today at ... known that cognitive rehabilitation programs are proven to be effective in improving cognitive ...
(Date:2/25/2017)... ... 25, 2017 , ... FCPX users now have the ability to sharpen a ... ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, ... spectrum tools users can visually see the color range effected with ease all within ...
Breaking Medicine News(10 mins):